0000899243-19-017000.txt : 20190614
0000899243-19-017000.hdr.sgml : 20190614
20190614160526
ACCESSION NUMBER: 0000899243-19-017000
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190613
FILED AS OF DATE: 20190614
DATE AS OF CHANGE: 20190614
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Perkins Adelene Q
CENTRAL INDEX KEY: 0001375124
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-31141
FILM NUMBER: 19898892
MAIL ADDRESS:
STREET 1: C/O INFINITY PHARMACEUTICALS, INC.
STREET 2: 780 MEMORIAL DRIVE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: INFINITY PHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0001113148
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 330655706
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 784 MEMORIAL DRIVE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 6174531000
MAIL ADDRESS:
STREET 1: 784 MEMORIAL DRIVE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
FORMER COMPANY:
FORMER CONFORMED NAME: INFINITY PHARMACEUTICALS, INC./NEW/
DATE OF NAME CHANGE: 20060913
FORMER COMPANY:
FORMER CONFORMED NAME: DISCOVERY PARTNERS INTERNATIONAL INC
DATE OF NAME CHANGE: 20000428
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-06-13
0
0001113148
INFINITY PHARMACEUTICALS, INC.
INFI
0001375124
Perkins Adelene Q
C/O INFINITY PHARMACEUTICALS, INC.
784 MEMORIAL DRIVE
CAMBRIDGE
MA
02139
1
1
0
0
Chief Executive Officer
Stock Option (right to buy)
1.24
2019-06-13
4
A
0
242000
0.00
A
2029-01-03
Common Stock
242000
242000
D
This option was approved by the Compensation Committee of the Board of Directors of Infinity Pharmaceuticals, Inc., on January 4, 2019, contingent upon shareholder approval of the Company's 2019 Equity Incentive Plan under which the options were granted, which was approved by shareholders on June 13, 2019.
The option vests as to 1/48th of the shares on January 31, 2019 and vests as to 1/48th of the shares at the end of each calendar month thereafter.
/s/ Adelene Q. Perkins
2019-06-13